Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07799933 in Advanced Solid Tumors with BRAF Alterations
NCT05355701Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of PF-07799933 in solid tumor, melanoma, colorectal cancer (CRC) and 3 more (9 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
PF-07799933
03
Conditions
solid tumormelanomacolorectal cancer (CRC)non-small cell lung cancer (NSCLC)thyroid cancer
Beyond the preview
Go deeper on NCT05355701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355701.